We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Medigus Ltd | NASDAQ:MDGS | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.36 | 2.52 | 2.59 | 0 | 01:00:00 |
CUSIP No.
58471G102
|
SCHEDULE 13D |
Page 2 of 10 Pages
|
1
|
NAME OF REPORTING
PERSONS
OrbiMed Israel BioFund GP Limited Partnership
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)
o
(b)
o
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
N/A
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
State of Israel
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
7,407,282 (1)
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
7,407,282 (1)
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,407,282 (1)
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.86% (2)
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
PN
|
(1)
|
Includes 3,000,000 Ordinary Shares (as defined below) evidenced by 60,000 American Depositary Shares (“
ADSs
”) and 1,054,524 Ordinary Shares issuable upon the exercise of warrants.
|
(2)
|
This percentage is calculated based upon 151,258,784 of the Issuer’s Ordinary Shares outstanding as of July 21, 2017, based upon information received from the Issuer.
|
CUSIP No.
58471G102
|
SCHEDULE 13D |
Page 3 of 10 Pages
|
1
|
NAME OF REPORTING
PERSONS
OrbiMed Israel GP Ltd.
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)
o
(b)
o
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
N/A
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
State of Israel
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
7,407,282 (1)
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
7,407,282 (1)
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,407,282 (1)
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.86% (2)
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
CO
|
(1)
|
Includes 3,000,000 Ordinary Shares (as defined below) evidenced by 60,000 American Depositary Shares (“
ADSs
”) and 1,054,524 Ordinary Shares issuable upon the exercise of warrants.
|
(2)
|
This percentage is calculated based upon 151,258,784 of the Issuer’s Ordinary Shares outstanding as of July 21, 2017, based upon information received from the Issuer.
|
Item 1. |
Security and Issuer.
|
Item 2. |
Identity and Background.
|
Item 3. |
Source and Amount of Funds or Other Consideration.
|
Item 4. |
Purpose of Transaction.
|
Item 5. |
Interest in Securities of the Issuer.
|
Item 6. |
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
|
Item 7. |
Materials to be Filed as Exhibits.
|
Exhibit No.
|
Description
|
A.
|
Joint Filing Agreement between OrbiMed Israel GP Ltd. and OrbiMed Israel BioFund GP Limited Partnership
|
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP | |||
By: | OrbiMed Israel GP Ltd., its General Partner | ||
|
By:
|
/s/ Nissim Darvish | |
Nissim Darvish | |||
Director | |||
ORBIMED ISRAEL GP LTD. | |||
By:
|
/s/ Nissim Darvish | ||
Nissim Darvish | |||
Director |
Name
|
Position with Reporting
Person |
Principal Occupation
|
Carl L. Gordon
American citizen
|
Director
|
Member
OrbiMed Advisors LLC
|
Nissim Darvish
|
Director
|
Senior Managing Director
OrbiMed Israel Partners Limited
|
Jonathan T. Silverstein
American citizen
|
Director
|
Member
OrbiMed Advisors LLC |
1 Year Medigus Chart |
1 Month Medigus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions